United Therapeutics (UTHR) statistics

Analysts' price targets and ratings, ownership, short interest, trading figures and dates for United Therapeutics, as the data feed reports them.

Analysts' mean target, 14 analysts
$687.14
17.8% above the price

The 14 analysts reported by the data feed have a mean price target for United Therapeutics of $687.14, 17.8% above the $583.20 price (range $390.00–$850.00). 5.04% of the float was sold short as of Oct 30, 2026. Institutions hold 105.1% of the shares and insiders 2.1%. Source: Yahoo Finance, read Nov 17, 2026.

Key facts

Analysts' mean target
$687.14+17.8% vs price
Analysts
14
Short interest
5.04%of float, Oct 30, 2026
Short ratio
2.12 days
Institutions
105.1%
Insiders
2.06%
Beta
0.48

Figures read . Source: Yahoo Finance (quoteSummary: key statistics, financial data, recommendation trend, major holders, insider purchases, calendar events). Analysts' targets and ratings, ownership and short interest are the data feed's figures and can lag the filings and exchange reports they come from. Figures, not advice.

Analysts' consensus as reported by the data feed

14 analysts covering United Therapeutics, as the data feed counts them. Price targets and ratings are other people's estimates — not facts about the company, and not advice. Distances are from the latest price the feed gave with these figures, $583.20.

Analysts' price targets for United Therapeutics
Mean price target$687.1417.8% above the price (+17.8%)
Median price target$711.5022.0% above the price (+22.0%)
Highest target$850.0045.7% above the price (+45.7%)
Lowest target$390.0033.1% below the price (−33.1%)
Analysts with a target14

Ratings this month · 15 analysts

Strong buy 3(20%)Buy 9(60%)Hold 2(13%)Sell 1(7%)
Analysts' ratings of United Therapeutics this month, by rating
RatingAnalystsShare
Strong buy320%
Buy960%
Hold213%
Sell17%
Strong sell00%

The feed averages these to 1.73 on its scale of 1 (strong buy) to 5 (strong sell), which it labels “buy”.

Who owns United Therapeutics

Ownership of United Therapeutics
Held by institutions105.1%1,186 institutions; percent of shares outstanding
Held by institutions, of the float107.3%
Held by insiders2.06%percent of shares outstanding
Shares outstanding42.59M
Float38.91Mshares available to trade
Insiders' net purchases, six months+16.52K147 purchases (1.31M shares), 143 sales (1.3M shares)

Percentages are of shares outstanding unless the row says float. Insiders' net purchases are shares bought minus shares sold by insiders, as the data feed totals their reported trades.

Short interest as reported by the data feed

Shares sold short and not yet covered, as of Oct 30, 2026. Short interest is counted twice a month, so this is not today's figure.

Short interest in United Therapeutics
Shares short1.84Mas of Oct 30, 2026
Percent of float5.04%shares short ÷ float
Percent of shares outstanding4.31%shares short ÷ shares outstanding
Short ratio (days to cover)2.12shares short ÷ average daily volume

United Therapeutics short interest from FINRA, with its history

Trading figures

Trading figures for United Therapeutics
Beta0.48movement against the market; 1 moves with it
52-week high$614.23
52-week low$455.63
Average volume, 3 months703.06Kshares a day
Average volume, 10 days527.59Kshares a day

Questions and answers

What is the analysts' price target for United Therapeutics (UTHR)?

As reported by the data feed, the mean price target of the 14 analysts covering United Therapeutics is $687.14, 17.8% above the latest price of $583.20. The highest target is $850.00 and the lowest $390.00. Targets are analysts' estimates, not facts about the company and not advice.

How do analysts rate United Therapeutics stock?

Of the 15 ratings the data feed reports for the current month, 3 are strong buy, 9 buy, 2 hold, 1 sell and 0 strong sell.

How many United Therapeutics shares are sold short?

As reported by the data feed, 1.84M shares were sold short, 5.04% of the float as of Oct 30, 2026. At the average daily volume that is 2.12 days to cover. Short interest is reported twice a month; it is not today's figure.

Who owns United Therapeutics stock?

As reported by the data feed, institutions hold 105.1% of the shares (1,186 institutions) and insiders 2.1%. There are 42.59M shares outstanding, of which 38.91M are in the float.

How much does United Therapeutics stock move with the market?

Its beta, as reported by the data feed, is 0.48: a beta above 1 means the share has tended to move more than the market, below 1 less. Over the past 52 weeks it traded between $455.63 and $614.23.

Cite this page

Funkfolio, “United Therapeutics (UTHR) statistics and analyst targets”, data as of 17 November 2026. https://funkfolio.com/stock/UTHR/statistics

Underlying data: Yahoo Finance.